Cartesian Therapeutics' (RNAC) Buy Rating Reiterated at HC W

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Several other analysts also recently weighed in on the company. Needham & Company LLC restated a buy […]

Related Keywords

United States , American , Leerink Partnrs , Timothya Springer , Hall Laurie , Sg Americas Securities , American International Group Inc , Securities Exchange Commission , Delphi Financial Group Inc , Cartesian Therapeutics Inc , Cartesian Therapeutics Company Profile , Needham Company , Cartesian Therapeutics , Free Report , Therapeutics Trading Down , Get Free Report , Director Timothy , Exchange Commission , Lauriej Trustee , International Group , Financial Markets , Delphi Financial Group , Cartesian Therapeutics Daily ,